This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Immunologic Disorders  • Randomized Controlled Trial  • Neurology, Other  • Drug Therapy  • Alert me on articles by topic

An Open-Label Trial

Alireza Minagar, MD; J. Steven Alexander, PhD; Robert N. Schwendimann, MD; Roger E. Kelley, MD; Eduardo Gonzalez-Toledo, MD, PhD; Joaquim J. Jimenez, MD; Lucia Mauro, MS; Wenche Jy, PhD; Stacy J. Smith, BA

Arch Neurol. 2008;65(2):(doi:10.1001/archneurol.2007.41).

Objective  To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing-remitting multiple sclerosis (RRMS) having breakthrough disease activity.

Design  Open-label, 7-month trial.

Setting  Louisiana State University Health Sciences Center, Shreveport.

Patients  Fifteen patients with RRMS taking interferon beta-1a with breakthrough disease activity took doxycycline for 4 months. Patients underwent monthly neurologic examination, magnetic resonance imaging of the brain using triple-dose gadolinium, and safety blood work.

Interventions  Ongoing treatment with intramuscular interferon beta-1a plus oral doxycycline, 100 mg daily, for 4 months.

Main Outcome Measures  The primary end point was gadolinium-enhancing lesion number change, and the secondary end points were relapse rates, safety and tolerability of the combination of interferon beta-1a and doxycycline in patients with MS, Expanded Disability Status Scale score, serum matrix metalloproteinase-9 levels, and transendothelial migration of monocytes exposed to serum from patients with RRMS.

Results  Combination of doxycycline and interferon beta-1a treatment resulted in reductions in contrast-enhancing lesion numbers and posttreatment Expanded Disability Status Scale values (P < .001 for both). Only 1 patient relapsed. Multivariate analyses indicated correlations between decreased serum matrix metalloproteinase-9 levels and enhancing lesion activity reduction. Transendothelial migration of monocytes incubated with serum from patients with RRMS undergoing combination therapy was suppressed. Adverse effects were mild; no adverse synergistic effects of combination therapy or unexpected adverse events were reported.

Conclusions  Combination of intramuscular interferon beta-1a and oral doxycycline treatment was effective, safe, and well tolerated. Controlled clinical trials in larger cohorts of patients with MS are needed to evaluate the efficacy and tolerability of this combination.

Trial Registration  clinicaltrials.gov Identifier: NCT00246324

Author Affiliations: Departments of Neurology (Drs Minagar, Schwendimann, and Kelley and Ms Smith), Cellular and Molecular Physiology (Dr Alexander), and Radiology (Dr Gonzalez-Toledo), Louisiana State University Health Sciences Center, Shreveport; and Wallace H. Coulter Platelet Laboratory, Department of Medicine, University of Miami School of Medicine, Miami, Florida (Drs Jimenez and Jy and Ms Mauro).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Therapy for Whipple's disease--authors' response
Knaapen and Barrera
J Antimicrob Chemother 2008;61:969-970.
FULL TEXT